SG11201806599SA - Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human - Google Patents
Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in humanInfo
- Publication number
- SG11201806599SA SG11201806599SA SG11201806599SA SG11201806599SA SG11201806599SA SG 11201806599S A SG11201806599S A SG 11201806599SA SG 11201806599S A SG11201806599S A SG 11201806599SA SG 11201806599S A SG11201806599S A SG 11201806599SA SG 11201806599S A SG11201806599S A SG 11201806599SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- stopping
- human
- preventing
- Prior art date
Links
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 title abstract 3
- 239000003136 dopamine receptor stimulating agent Substances 0.000 title abstract 3
- 239000003149 muscarinic antagonist Substances 0.000 title abstract 3
- 239000000043 antiallergic agent Substances 0.000 title abstract 2
- 230000004329 axial myopia Effects 0.000 title abstract 2
- 229940052760 dopamine agonists Drugs 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 206010010741 Conjunctivitis Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 230000003266 anti-allergic effect Effects 0.000 abstract 1
- 230000001387 anti-histamine Effects 0.000 abstract 1
- 230000001022 anti-muscarinic effect Effects 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 230000003291 dopaminomimetic effect Effects 0.000 abstract 1
- 239000003889 eye drop Substances 0.000 abstract 1
- 229940012356 eye drops Drugs 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 230000000642 iatrogenic effect Effects 0.000 abstract 1
- 230000004379 myopia Effects 0.000 abstract 1
- 208000001491 myopia Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITUB2016A000876A ITUB20160876A1 (it) | 2016-02-19 | 2016-02-19 | Combinazione di un agente antiallergico con un antagonista muscarinico e/o un agonista dopaminergico per l'uso in prevenzione/ arresto di miopia assiale nell’uomo |
PCT/EP2017/053619 WO2017140846A1 (en) | 2016-02-19 | 2017-02-17 | Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201806599SA true SG11201806599SA (en) | 2018-09-27 |
Family
ID=55948995
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201806599SA SG11201806599SA (en) | 2016-02-19 | 2017-02-17 | Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human |
SG10202007417SA SG10202007417SA (en) | 2016-02-19 | 2017-02-17 | Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202007417SA SG10202007417SA (en) | 2016-02-19 | 2017-02-17 | Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human |
Country Status (13)
Country | Link |
---|---|
US (2) | US20200253951A1 (es) |
EP (1) | EP3416617A1 (es) |
JP (1) | JP2019505542A (es) |
KR (1) | KR20180117642A (es) |
CN (1) | CN108883060A (es) |
AU (1) | AU2017220640B2 (es) |
BR (1) | BR112018016845A2 (es) |
CA (1) | CA3013846A1 (es) |
CL (1) | CL2018002196A1 (es) |
IL (1) | IL260893B2 (es) |
IT (1) | ITUB20160876A1 (es) |
SG (2) | SG11201806599SA (es) |
WO (1) | WO2017140846A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201800005599A1 (it) * | 2018-05-22 | 2019-11-22 | Lente a contatto morbida | |
CN109044965A (zh) * | 2018-10-17 | 2018-12-21 | 广州大光制药有限公司 | 格隆溴铵的眼用药物组合物及医药用途 |
KR20230051130A (ko) * | 2020-06-02 | 2023-04-17 | 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | 선택적 히스타민 h1-수용체 길항제인 레보카바스틴 및 이의 유도체를 이용한 근시의 예방 및 치료를 위한 방법 및 조성물 |
CN114558069A (zh) | 2022-04-06 | 2022-05-31 | 杭州美依生物科技有限公司 | 一种眼部舒缓涂抹液及其制备方法 |
CN115137314B (zh) * | 2022-09-02 | 2022-11-15 | 首都医科大学附属北京同仁医院 | 近视风险评估方法、装置及穿戴设备 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69033246T2 (de) | 1989-06-21 | 1999-12-02 | Univ Pennsylvania | Behandlung und Regulierung der Augenentwicklung mit cholinergischen Agonisten |
CA2567981C (en) | 2004-05-28 | 2010-08-31 | Schering Corporation | Constrained himbacine analogs as thrombin receptor antagonists |
CA2594741A1 (en) | 2005-01-14 | 2006-07-20 | Schering Corporation | Synthesis of himbacine analogs |
BRPI0714587A2 (pt) * | 2006-07-25 | 2013-05-07 | Osmotica Corp | suluÇço oftÁlmica aquosa e uso da nesna |
SG151148A1 (en) * | 2007-10-05 | 2009-04-30 | Singapore Health Services Pte | Method and/or kit for determining response to muscarinic receptor antagonist treatment |
ITMO20100369A1 (it) * | 2010-12-30 | 2012-07-01 | Enable Innovations Srl | Gamma di prodotti per uso oftalmico. |
-
2016
- 2016-02-19 IT ITUB2016A000876A patent/ITUB20160876A1/it unknown
-
2017
- 2017-02-17 KR KR1020187026872A patent/KR20180117642A/ko not_active Application Discontinuation
- 2017-02-17 WO PCT/EP2017/053619 patent/WO2017140846A1/en active Application Filing
- 2017-02-17 CN CN201780011993.4A patent/CN108883060A/zh active Pending
- 2017-02-17 SG SG11201806599SA patent/SG11201806599SA/en unknown
- 2017-02-17 US US15/999,784 patent/US20200253951A1/en not_active Abandoned
- 2017-02-17 JP JP2018543132A patent/JP2019505542A/ja active Pending
- 2017-02-17 EP EP17710482.5A patent/EP3416617A1/en active Pending
- 2017-02-17 CA CA3013846A patent/CA3013846A1/en active Pending
- 2017-02-17 SG SG10202007417SA patent/SG10202007417SA/en unknown
- 2017-02-17 AU AU2017220640A patent/AU2017220640B2/en active Active
- 2017-02-17 BR BR112018016845A patent/BR112018016845A2/pt not_active Application Discontinuation
-
2018
- 2018-07-31 IL IL260893A patent/IL260893B2/en unknown
- 2018-08-09 CL CL2018002196A patent/CL2018002196A1/es unknown
-
2023
- 2023-01-12 US US18/096,165 patent/US20230172904A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2018133026A3 (es) | 2020-04-24 |
CL2018002196A1 (es) | 2019-01-25 |
WO2017140846A1 (en) | 2017-08-24 |
US20230172904A1 (en) | 2023-06-08 |
IL260893B1 (en) | 2023-04-01 |
KR20180117642A (ko) | 2018-10-29 |
JP2019505542A (ja) | 2019-02-28 |
AU2017220640A1 (en) | 2018-10-04 |
US20200253951A1 (en) | 2020-08-13 |
IL260893A (es) | 2018-09-20 |
IL260893B2 (en) | 2023-08-01 |
AU2017220640B2 (en) | 2022-08-25 |
BR112018016845A2 (pt) | 2018-12-26 |
CN108883060A (zh) | 2018-11-23 |
ITUB20160876A1 (it) | 2017-08-19 |
EP3416617A1 (en) | 2018-12-26 |
SG10202007417SA (en) | 2020-09-29 |
RU2018133026A (ru) | 2020-03-19 |
CA3013846A1 (en) | 2017-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201806599SA (en) | Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human | |
SG11201907034PA (en) | Methods of treating influenza | |
SG11201900596XA (en) | Cannabis composition | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201907435PA (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201900501RA (en) | Cannabis composition | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
SG11201900665VA (en) | Cannabis composition | |
SG11201809822SA (en) | Atropine-containing aqueous composition | |
SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea | |
SG11201808650QA (en) | Methods of treating ocular conditions | |
SG11201811093RA (en) | Antimicrobial compounds and methods for use thereof | |
SG11201805195YA (en) | Composition comprising botulinum toxin | |
SG11201902974PA (en) | Combination of a pd-1 antagonist and eribulin for treating urothelial cancer | |
SG11201811655SA (en) | Trpa1 antagonists for treatment of dry eye, ocular pain and inflammation | |
SG11201803816RA (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease |